1. India Stocks

  2. •

    Healthcare

  3. •

    Medical - Pharmaceuticals
Welcure Drugs & Pharmaceuticals Limited

Welcure Drugs & Pharmaceuticals Limited

WELCURE.BO
Welcure Drugs & Pharmaceuticals LimitedIN flagBombay Stock Exchange
0.26
INR
- -
- -
29.21MMarket Cap
Welcure Drugs & Pharmaceuticals Limited
WELCURE.BO
(Bombay Stock Exchange)

Recent

price

0.26

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
FRC
0.01
- -
0.03
0.03
0.04
0.08
0.01
- -
0.07
0.07
0.11
0.09
- -
- -
0.2
- -
3.82
Revenue per Share
0.09
-0.08
0.01
- -
- -
0.07
- -
- -
- -
-0.01
0.05
0.02
0.01
-0.01
0.02
- -
-0.18
Basic EPS, GAAP
-0.19
-0.19
0.01
- -
0.01
-0.04
- -
- -
- -
-0.01
0.03
0.02
0.01
-0.01
-1.79
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-0.01
-0.2
-0.19
10
-0.19
-0.11
-0.01
-0.01
-0.1
-0.11
-0.07
-0.05
0.09
0.08
0.91
- -
1.29
Book Value per Share
- -
-0.08
-0.07
-0.07
-0.06
0.01
- -
- -
0.02
0.01
0.06
0.08
0.1
0.09
0.83
- -
1.01
Tangible Book Value per Share
149
12
12
12
12
12
133
133
12
12
12
12
148
149
1,238
- -
956
Basic Weighted Avg Shares
1
- -
- -
- -
1
1
1
- -
1
1
1
1
- -
- -
246
3,655
3,655
Sales/Revenue/Turnover
1,660.45
- -
29.75
4.53
6.9
82.21
30.8
-41
2.91
-11.88
41.26
22.52
- -
- -
3.54
-1.9
-2.02
Operating Margin (%)
4
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
14
-1
- -
- -
- -
1
- -
- -
- -
- -
1
- -
1
-2
22
-55
-170
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
21.94
- -
75.5
Effective Tax Rate (%)
1,624.61
- -
39.48
7.81
11.58
85.59
30.8
-38.8
4.88
-11.39
41.36
22.46
- -
- -
8.84
-1.5
-4.65
Profit Margin (%)
- -
-1
-1
-1
-1
- -
- -
- -
- -
- -
- -
1
- -
- -
1,409
-556
-556
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
1,232
- -
- -
LT Debt
- -
-1
-1
-1
-1
- -
- -
- -
- -
- -
1
1
15
13
1,025
970
970
Total Equity
148.43
- -
- -
- -
- -
-263.49
108.66
- -
10.63
- -
130.47
29.11
-16.84
- -
0.6
- -
18.28
Return on Invested Capital (%)
173.06
- -
-5.34
0.05
0.1
-47.02
-22.05
- -
-3.01
- -
-50.7
-33.97
15.56
- -
1.83
- -
19.97
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-13.69
3.82
-4.65
-14.4
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
ST Debt
- -
- -
- -
LT Borrowings
1,232
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,236
- -
1,236
Market Capitalization
477
401
230

Working Capital

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
Total Current Assets
5,480
- -
3,575
Cash, Cash Equivalents & STI
1
- -
6
Accounts Receivable, Net
3,845
- -
2,134
Inventories
1,435
- -
1,435
Total Current Liabilities
3,754
- -
4,132
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
964.75%
1,818.71%
-5.36%
Free Cash Flow
17,253.27%
34,803.42%
-100.78%
Net Income, GAAP
-307.93%
-338.46%
-352.99%
Sales/Revenue/Turnover
- -
- -
1,388.95%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
246
88
212
246
2026
2,999
656
- -
- -
3,655

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
-0.01
-0.02
- -
-0.01
2025
-0.02
0.23
- -
0.02
0.02
2026
2.07
0.07
0.01
-0.4
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
COSMOS Pharmaceutical Corporation (3349.T)
Sundrug Co.,Ltd. (9989.T)
Rein Therapeutics Inc. (RNTX)
POZEN Inc. (POZN)
Mind Medicine (MindMed) Inc. (MMDCF)
Synvista Therapeutics, Inc. (SYNI)
Business
Welcure Drugs & Pharmaceuticals Limited is an Indian pharmaceutical company engaged in the manufacturing, marketing, and distribution of a wide range of pharmaceutical formulations and active pharmaceutical ingredients (APIs). The company offers a diverse portfolio of products including tablets, capsules, syrups, injectables, ointments, and powders. Its product offerings cover various therapeutic categories such as antibiotics, analgesics, anti-inflammatory drugs, anti-diabetic drugs, cardiovascular drugs, gastrointestinal drugs, and dermatological products. Welcure Drugs serves both domestic and international markets with a focus on innovation and quality. Founded in 1962, Welcure Drugs is headquartered in Mumbai, Maharashtra, India. The company operates through multiple production facilities and maintains a broad distribution network across India and abroad. It targets healthcare providers, hospitals, clinics, and retail pharmacies as its primary customer base. In recent developments within the last 1-2 years, Welcure Drugs & Pharmaceuticals Limited has pursued strategic expansion through new product launches and increased focus on export markets. The company also continues to strengthen partnerships and collaborations to enhance its research and development capabilities. There have been no major name changes or reorganizations reported recently. The company remains committed to broadening its therapeutic product lines and geographic reach in Asia and other emerging markets. Overall, Welcure Drugs & Pharmaceuticals Limited is recognized for its comprehensive range of pharmaceutical products, sustained operational growth, and ongoing initiatives that align with its strategy to strengthen its presence in the competitive pharmaceutical industry.